Miodrag Janić

Prof. Dr. Miodrag Janić

Ljubljana University Medical Centre, Ljubljana, Slovenia
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Miodrag JanićMiodrag Janić
Miodrag Janić
MLMojca Lunder
Mojca Lunder
MŠMišo Šabovič
Mišo Šabovič
The world population is aging and the number of old people is continuously increasing. Arterial structure and function change with age, progressively leading to arterial stiffening. Arterial stiffness is best characterized by measurement of pulse wave velocity (PWV), which is its surrogate marker. It has been shown that PWV could improve cardiovascular event prediction in models that included standard risk factors. Consequently, it might therefore enable better identification of populations at high-risk of cardiovascular morbidity and mortality. The present review is focused on a survey of different pharmacological therapeutic options for decreasing arterial stiffness. The influence of several groups of drugs is described: antihypertensive drugs (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, beta-blockers, diuretics, and nitrates), statins, peroral antidiabetics, advanced glycation end-products (AGE) cross-link breakers, anti-inflammatory drugs, endothelin-A receptor antagonists, and vasopeptidase inhibitors. All of these have shown some effect in decreasing arterial stiffness. Nevertheless, further studies are needed which should address the influence of arterial stiffness diminishment on major adverse cardiovascular and cerebrovascular events (MACCE).

3 December 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
Mojca LunderMojca Lunder
Mojca Lunder
Miodrag JanićMiodrag Janić
Miodrag Janić
MJMiha Japelj
Miha Japelj
AJAndrej Juretič
Andrej Juretič
AJAndrej Janež
Andrej Janež
MŠMišo Šabovič
Mišo Šabovič
Background: Deteriorated arterial function and high incidence of cardiovascular events characterise diabetes mellitus. Metformin and recent antidiabetic drugs, SGLT2 inhibitors, reduce cardiovascular events. We explored the possible effects of empagliflozin’s effect on top of metformin treatment on endothelial function and arterial stiffness parameters in type 1 diabetes mellitus (T1DM) patients. Methods: Forty T1DM patients were randomised into three treatment groups: (1) empagliflozin (25 mg daily), (2) metformin (2000 mg daily) and (3) empagliflozin/metformin (25 mg daily and 2000 mg daily, respectively). The fourth group received placebo. Arterial function was assessed at inclusion and after 12 weeks treatment by: endothelial function [brachial artery flow-mediated dilation (FMD), reactive hyperaemia index (RHI)], arterial stiffness [pulse wave velocity (PWV) and common carotid artery stiffness (β-stiffness)]. For statistical analysis one-way analysis of variance with Bonferroni post-test was used. Results: Empagliflozin on top of metformin treatment significantly improved endothelial function as did metformin after 12 weeks of treatment: FMD [2.6-fold (P < 0.001) vs. 1.8-fold (P < 0.05)] and RHI [1.4-fold (P < 0.01) vs. 1.3-fold (P < 0.05)]. Empagliflozin on top of metformin treatment was superior to metformin in improving arterial stiffness parameters; it significantly improved PWV and β-stiffness compared to metformin [by 15.8% (P < 0.01) and by 36.6% (P < 0.05), respectively]. Metformin alone did not influence arterial stiffness. Conclusion: Empagliflozin on top of metformin treatment significantly improved arterial stiffness compared to metformin in T1DM patients. Endothelial function was similarly improved in all treatment groups. Empagliflozin seems to possess a specific capacity to decrease arterial stiffness, which could support its cardioprotective effects observed in large clinical studies. Trial registration Clinical trial registration: NCT03639545

5 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Miodrag JanićMiodrag Janić
Miodrag Janić
Andrej JanežAndrej Janež
Andrej Janež
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
MANFREDI RIZZOMANFREDI RIZZO
MANFREDI RIZZO
As reported in the World Obesity Atlas 2024 by the World Obesity Federation, the projections for 2035 suggest that more than 1

1 January 2014 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
MŠMišo Šabovič
Mišo Šabovič
ASAjda Skarlovnik
Ajda Skarlovnik
Miodrag JanićMiodrag Janić
Miodrag Janić
MLMojca Lunder
Mojca Lunder
MTMartina Turk
Martina Turk
Background:Statin use is frequently associated with muscle-related symptoms. Coenzyme Q10 supplementation has yielded conflicting results in decreasing statin myopathy. Herein, we tested whether coenzyme Q10 supplementation could decrease statin-asso...

Verified
Journal Article
Open access
PDF file
JNJovana Nikolajević
Jovana Nikolajević
Miodrag JanićMiodrag Janić
Miodrag Janić
MŠMišo Šabovič
Mišo Šabovič
In diabetic patients, cardiomyopathy is an important cause of heart failure, but its pathophysiology has not been completely understood thus far. Myocardial hypertrophy and diastolic dysfunction have been considered the hallmarks of diabetic cardiomyopathy (DCM), while systolic function is affected in the latter stages of the disease. In this article we propose the potential pathophysiological mechanisms responsible for myocardial hypertrophy and increased myocardial stiffness leading to diastolic dysfunction in this specific entity. According to our model, increased myocardial stiffness results from both cellular and extracellular matrix stiffness as well as cell–matrix interactions. Increased intrinsic cardiomyocyte stiffness is probably the most important contributor to myocardial stiffness. It results from the impairment in cardiomyocyte cytoskeleton. Several other mechanisms, specifically affected by diabetes, seem to also be significantly involved in myocardial stiffening, i.e., impairment in the myocardial nitric oxide (NO) pathway, coronary microvascular dysfunction, increased inflammation and oxidative stress, and myocardial sodium glucose cotransporter-2 (SGLT-2)-mediated effects. Better understanding of the complex pathophysiology of DCM suggests the possible value of drugs targeting the listed mechanisms. Antidiabetic drugs, NO-stimulating agents, anti-inflammatory agents, and SGLT-2 inhibitors are emerging as potential treatment options for DCM.

1 April 2011 in Atherosclerosis
Verified
Journal Article
Closed access
Mojca LunderMojca Lunder
Mojca Lunder
Miodrag JanićMiodrag Janić
Miodrag Janić
SHSara Habjan
Sara Habjan
MŠMišo Šabovič
Mišo Šabovič